Recently, monitoring data from the World Health Organization showed that the intensity of the new coronavirus activity in Europe, the Americas and other regions has increased. As the novel coronavirus continues to mutate, the current novel coronavirus variants KP.2 and KP.1.1 have become dominant in these places.

WIZ's two reagents, HBA1C assay kits (fluorescent immunochromatography) and the SARS-CoV-2 Antigen Rapid Test (Colloidal gold) (Anterior nasal) have been approved by the Medical Device Authority (MDA) of Malaysia and began market access.

According to the latest HSC Common List published on October 17, 2022, the SARS-CoV-2 Antigen Rapid Test produced by Wizbiotech has been listed in HSC Common List Class A.

In 2015, Xiamen Wiz Biotech Co., Ltd obtained high-tech enterprise certificate after the relevant government departments strict assessment. Wiz Biotech will take this opportunity to continuously carry out technological innovation and improve the technical level of the enterprise.